Vir Biotechnology, Inc. (VIR) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Vir Biotechnology, Inc. (VIR) Bundle
Looking to assess the intrinsic value of Vir Biotechnology, Inc.? Our (VIR) DCF Calculator integrates real-world data with comprehensive customization options, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .7 | 67.2 | 1,087.1 | 1,580.5 | 86.2 | 176.9 | 363.0 | 745.1 | 1,529.2 | 3,138.4 |
Revenue Growth, % | 0 | 9357.81 | 1516.58 | 45.39 | -94.55 | 105.24 | 105.24 | 105.24 | 105.24 | 105.24 |
EBITDA | -173.5 | -289.8 | 420.8 | 833.1 | -664.9 | -73.8 | -151.4 | -310.8 | -637.9 | -1,309.3 |
EBITDA, % | -24396.91 | -430.96 | 38.71 | 52.71 | -771.47 | -41.72 | -41.72 | -41.72 | -41.72 | -41.72 |
Depreciation | 4.5 | 8.8 | 12.0 | 15.5 | 19.5 | 48.7 | 100.0 | 205.3 | 421.3 | 864.7 |
Depreciation, % | 635.3 | 13.11 | 1.1 | 0.98021 | 22.57 | 27.55 | 27.55 | 27.55 | 27.55 | 27.55 |
EBIT | -178.0 | -298.6 | 408.8 | 817.6 | -684.3 | -74.5 | -153.0 | -313.9 | -644.3 | -1,322.3 |
EBIT, % | -25032.21 | -444.06 | 37.6 | 51.73 | -794.04 | -42.13 | -42.13 | -42.13 | -42.13 | -42.13 |
Total Cash | 383.4 | 736.9 | 708.1 | 2,402.0 | 1,522.4 | 164.5 | 337.7 | 693.1 | 1,422.6 | 2,919.6 |
Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | 773.1 | .0 | .0 | 25.2 | 51.6 | 106.0 | 217.5 | 446.4 |
Account Receivables, % | 0 | 0 | 71.12 | 0 | 0 | 14.22 | 14.22 | 14.22 | 14.22 | 14.22 |
Inventories | .0 | .0 | 8.6 | .0 | .0 | .3 | .6 | 1.2 | 2.4 | 5.0 |
Inventories, % | 0 | 0 | 0.79057 | 0 | 0 | 0.15811 | 0.15811 | 0.15811 | 0.15811 | 0.15811 |
Accounts Payable | 5.9 | 5.1 | 6.5 | 6.4 | 6.3 | 41.0 | 84.2 | 172.7 | 354.5 | 727.5 |
Accounts Payable, % | 827.14 | 7.55 | 0.59987 | 0.40633 | 7.35 | 23.18 | 23.18 | 23.18 | 23.18 | 23.18 |
Capital Expenditure | -8.9 | -6.5 | -21.8 | -68.0 | -21.6 | -49.9 | -102.4 | -210.2 | -431.5 | -885.6 |
Capital Expenditure, % | -1257.38 | -9.74 | -2.01 | -4.3 | -25.03 | -28.22 | -28.22 | -28.22 | -28.22 | -28.22 |
Tax Rate, % | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 | 2.09 |
EBITAT | -178.1 | -298.7 | 393.0 | 559.1 | -670.0 | -68.9 | -141.5 | -290.3 | -595.9 | -1,223.0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -176.7 | -297.2 | -397.1 | 1,288.2 | -672.2 | -60.9 | -127.5 | -261.7 | -537.1 | -1,102.2 |
WACC, % | 6.37 | 6.37 | 6.35 | 6.21 | 6.36 | 6.33 | 6.33 | 6.33 | 6.33 | 6.33 |
PV UFCF | ||||||||||
SUM PV UFCF | -1,618.7 | |||||||||
Long Term Growth Rate, % | 4.00 | |||||||||
Free cash flow (T + 1) | -1,146 | |||||||||
Terminal Value | -49,168 | |||||||||
Present Terminal Value | -36,172 | |||||||||
Enterprise Value | -37,791 | |||||||||
Net Debt | -130 | |||||||||
Equity Value | -37,661 | |||||||||
Diluted Shares Outstanding, MM | 134 | |||||||||
Equity Value Per Share | -280.78 |
What You Will Get
- Real VIR Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Vir Biotechnology’s future outlook.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Vir Biotechnology’s historical financial records and pre-filled projections.
- Customizable Inputs: Modify discount rates, tax percentages, revenue growth, and profit margins.
- Real-Time Insights: Observe Vir Biotechnology’s intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs showcase valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based VIR DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Vir Biotechnology’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial analysis.
Why Choose This Calculator for Vir Biotechnology, Inc. (VIR)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and industry specialists.
- Accurate Data: Vir Biotechnology’s historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Comprehensive instructions lead you through each step of the calculation.
Who Should Use This Product?
- Investors: Evaluate Vir Biotechnology’s valuation prior to making investment decisions.
- CFOs and Financial Analysts: Enhance efficiency in valuation procedures and assess financial forecasts.
- Startup Founders: Understand the valuation methods applied to prominent biotech firms like Vir Biotechnology.
- Consultants: Create detailed valuation reports for your clients in the biotech sector.
- Students and Educators: Utilize real-world data from Vir Biotechnology to learn and teach valuation methodologies.
What the Template Contains
- Pre-Filled Data: Contains Vir Biotechnology's historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for WACC calculation based on user-defined inputs.
- Key Financial Ratios: Assess Vir Biotechnology's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.